UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 21,781 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 26.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 104,855 shares of the company's stock after acquiring an additional 21,781 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.23% of Pacira BioSciences worth $1,975,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in PCRX. Empowered Funds LLC increased its stake in Pacira BioSciences by 5.1% in the fourth quarter. Empowered Funds LLC now owns 229,485 shares of the company's stock valued at $4,323,000 after acquiring an additional 11,149 shares during the last quarter. Principal Financial Group Inc. boosted its position in Pacira BioSciences by 4.2% in the fourth quarter. Principal Financial Group Inc. now owns 257,733 shares of the company's stock valued at $4,856,000 after buying an additional 10,306 shares in the last quarter. Ieq Capital LLC acquired a new stake in Pacira BioSciences in the fourth quarter valued at approximately $291,000. Impax Asset Management Group plc boosted its position in Pacira BioSciences by 14.8% in the fourth quarter. Impax Asset Management Group plc now owns 540,027 shares of the company's stock valued at $10,174,000 after buying an additional 69,424 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Pacira BioSciences by 11.8% during the fourth quarter. Bank of New York Mellon Corp now owns 396,399 shares of the company's stock worth $7,468,000 after purchasing an additional 41,881 shares during the period. 99.73% of the stock is owned by institutional investors.

Pacira BioSciences Stock Down 2.1%

Pacira BioSciences stock traded down $0.53 during midday trading on Wednesday, hitting $24.34. 888,688 shares of the stock were exchanged, compared to its average volume of 973,433. Pacira BioSciences, Inc. has a 52-week low of $11.16 and a 52-week high of $29.95. The stock has a market capitalization of $1.13 billion, a price-to-earnings ratio of -11.99 and a beta of 0.52. The business's 50-day moving average price is $25.57 and its 200-day moving average price is $23.48. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on PCRX shares. Barclays lifted their target price on shares of Pacira BioSciences from $17.00 to $24.00 and gave the stock an "overweight" rating in a research note on Friday, February 28th. Wall Street Zen raised shares of Pacira BioSciences from a "hold" rating to a "buy" rating in a research note on Friday, June 6th. HC Wainwright lifted their price target on shares of Pacira BioSciences from $48.00 to $65.00 and gave the company a "buy" rating in a research note on Tuesday, April 8th. Finally, Needham & Company LLC decreased their price target on shares of Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating for the company in a research note on Friday, May 9th. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, Pacira BioSciences currently has a consensus rating of "Hold" and an average price target of $26.44.

Insider Buying and Selling at Pacira BioSciences

In other news, SVP Lauren Riker sold 5,578 shares of the business's stock in a transaction that occurred on Wednesday, June 4th. The shares were sold at an average price of $26.21, for a total value of $146,199.38. Following the sale, the senior vice president now owns 59,564 shares of the company's stock, valued at $1,561,172.44. The trade was a 8.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 6.40% of the company's stock.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.